Arkadios Wealth Advisors Makes New $550,000 Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Arkadios Wealth Advisors has invested approximately $550,000 in Supernus Pharmaceuticals by purchasing 16,799 shares during the first quarter.
• Supernus Pharmaceuticals' stock price increased to $37.53, with a market capitalization of $2.10 billion and a PE ratio of 33.81.
• Wall Street analysts have recently upgraded Supernus Pharmaceuticals from a "hold" to a "buy" rating, with Cantor Fitzgerald setting a price target of $42.00.

Arkadios Wealth Advisors purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 16,799 shares of the specialty pharmaceutical company's stock, valued at approximately $550,000.

A number of other large investors also recently bought and sold shares of SUPN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Supernus Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after acquiring an additional 1,083 shares in the last quarter. Two Sigma Advisers LP raised its holdings in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after acquiring an additional 1,000 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Supernus Pharmaceuticals by 3.2% during the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after purchasing an additional 9,590 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Supernus Pharmaceuticals by 6.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after acquiring an additional 3,495 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Supernus Pharmaceuticals by 63.6% during the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock worth $579,000 after acquiring an additional 6,867 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 0.8%

Shares of NASDAQ:SUPN traded down $0.32 during trading on Friday, hitting $41.14. 617,019 shares of the company's stock traded hands, compared to its average volume of 625,580. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $43.62. The company has a market cap of $2.30 billion, a price-to-earnings ratio of 35.78 and a beta of 0.74. The company has a 50-day moving average price of $33.24 and a 200-day moving average price of $33.45.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SUPN. Cantor Fitzgerald increased their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.